Thu, October 24, 2019
Wed, October 23, 2019
Tue, October 22, 2019

Evan Seigerman Maintained (BIIB) at Sell with Increased Target to $260 on, Oct 23rd, 2019

Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Sell with Increased Target from $203 to $260 on, Oct 23rd, 2019.

Evan has made no other calls on BIIB in the last 4 months.



There is 1 other peer that has a rating on BIIB. Out of the 1 peers that are also analyzing BIIB, all agrees with Evan's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $250 on, Friday, June 28th, 2019


Similar Stocks and Investing Publications